Pidilizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pidilizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target PD-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6424H9920N1704O2002S48
Molar mass 147.43 kg/mol

Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 is it primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.

Clinical trials[edit]

It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.[citation needed] An add-on trial for multiple myeloma is ongoing.[5]

References[edit]